You're invited to join AF Stat™: A Call to Action for Atrial Fibrillation for the unveiling of the results of AFib in America: State Impact Reports. This first-of-its-kind analysis will feature state level statistics and resources related to the burden of atrial fibrillation (AFib) across the nation. To learn more, see: AF Stat Coalition to …
Read More
You're invited to join us for the launch of The Silver Book®: Thrombosis on March 23, 2011, at the Rayburn House Office Building on Capitol Hill in Washington, DC. If you can't make it, see how you can order a copy of the book, which features statistics on atrial fibrillation and strokes. See: Atrial Fibrillation …
Read More
Mellanie True Hills, founder and CEO of StopAfib.org and an atrial fibrillation survivor, is an invited speaker for the Fourth Annual Western Atrial Fibrillation Symposium taking place February 25-26, 2011 in Park City, UT. Symposium Director Dr. Nassir F. Marrouche says, " For the first time, the faculty includes someone representing the patients." Learn more: …
Read More
Note: In meetings with the FDA last week, representatives from WomenHeart and StopAfib.org became aware of the risk that potential funding cuts may significantly delay the FDA's work in reviewing and approving afib drugs and devices. Because of the potential impact on the afib community, we are publishing comments from WomenHeart as to what those …
Read More
Researchers at the Comprehensive Arrhythmia Research and Management Center (CARMA) in Utah have been studying the relationship between atrial fibrillation, atrial fibrosis, and catheter ablation outcomes for many years. Now, they’ve applied their knowledge of quantifying atrial fibrosis to stroke risk assessment and found that the amount of atrial fibrosis, not type of afib, is …
Read More
New research from Denmark shows that CHADS2 underestimates stroke risk. In the study, atrial fibrillation patients who were at intermediate risk with the CHADS2 scoring system had more than twice the stroke rate of those defined by the enhanced CHA2DS2-VASc tool as being at intermediate risk. While CHADS2 deemed 32.3% of patients to have intermediate …
Read More
In this video, Dr. Kenneth Ellenbogen talks about important information presented at the American Heart Association Scientific Sessions 2010. First he talked about the ROCKET AF clinical trial of rivaroxaban, a new drug that is an alternative to warfarin (Coumadin), as well as another alternative, the recently-approved dabigatran. He provided scenarios as to how these drugs …
Read More
Hybrid ablation is an emerging treatment for patients with persistent and longstanding persistent atrial fibrillation. It is a dual approach, in which an electrophysiologist ablates from inside the heart and the cardiac surgeon ablates on the outside the heart. Dr. James Edgerton, a cardiac surgeon at The Heart Hospital Baylor Plano in Texas, who spoke …
Read More
Check out the latest patient profile at StopAfib.org. Thanks to a catheter ablation that stopped her atrial fibrillation, Michele Straube, an outdoors enthusiast, will be undertaking an adventure that she is calling "Crossing the Heart of the Alps for Atrial Fibrillation Awareness." While you're there, check out all our patient stories.
Read More
Up to 30% of patients could have very late recurrence of atrial fibrillation after catheter ablation, according to research highlighted at the recent Boston AF Symposium. Very late recurrence, which is when atrial fibrillation resumes more than one year after ablation, may be the result of age, gender, type of afib, and existence of other …
Read More